AstraZeneca Group (AZN)
News
| May 23 | Are 3 Failed Phase 3 Trials Enough? Fool |
| May 23 | $AZN stop at 40 on 1/3. Have owned a ton of it since early '10. Cost basis ~46 (not inc. divies) by WallStreetBean |
| May 22 | Buffett and Woodford Agree on This One! Fool |
| May 22 | The FTSE's Cheapest Shares in the Storm Fool |
| May 18 | Friday Options Briefs: YHOO, MSI, AZN |
| May 18 | Report: Drug Makers Working on Emergency Supply Plan in Greece Fox Business |
| May 17 | Why U.K. Bonds Are for Losers Fool |
| May 17 | FDA Approves Generic Clopidogrels As Plavix Loses Patent Protection |
| May 17 | Myriad to Present Cancer Test Study |
| May 17 | Myriad to Present Cancer Test Study - Analyst Blog Zacks |
| May 17 | RT @SeemaCnbc Cancer data expected to move big pharma $JNJ $PFE $AZN by StockTwits |
| May 15 | $AMRN chat of potential take over target by $AZN for sometimes by tradeha |
| May 13 | $AZN “no longer operating in isolation as a pharmaceutical organization.” http://stks.co/3nwQ by WallStreetBean |
| May 08 | $AMRN and $FRX both are possible acquisition targets for $AZN by tradeha |
Profile
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - Major
AstraZeneca plc is a global pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by revenues and has operations in over 100 countries. It has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. AstraZeneca PLC markets its products primarily to primary care and specialist doctors, and other healthcare professionals through distributors or local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). AstraZeneca Group is down 13.83% over the last year vs S&P 500 Total Return up 2.33%, Eli Lilly and Company up 12.26%, and Bristol-Myers Squibb Company up 21.77%.
- AZN Total Returns
- ^SPXTR Total Returns
- LLY Total Returns
- BMY Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these AZN related companies
Pro Strategies Featuring AZN
Did AstraZeneca Group make it into our Pro Portfolio Strategies?
AZN Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other AZN Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AZN | 41.18 | +0.12 | +0.29% | 53.06B |
| AZK | 4.59 | +0.03 | +0.66% | 743.87M |
| AXS | 33.62 | -0.02 | -0.06% | 4.367B |
| AVT | 30.64 | +0.04 | +0.13% | 4.439B |
| AVK | 15.25 | +0.03 | +0.20% | |
| AVCA | 5.98 | -0.03 | -0.50% | 34.98M |
| AVA | 25.46 | +0.40 | +1.58% | 1.468B |
| AU | 36.41 | -0.15 | -0.41% | 14.08B |
| ATVI | 12.11 | -0.22 | -1.78% | 13.84B |
| ATV | 3.80 | -0.32 | -7.76% | 113.58M |
